Drug intelligence / Profile preview

artificial tears + benzalkonium chloride

Development stage
Unknown
Lead developer
Bausch & Lomb
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Artificial tears + benzalkonium chloride is a combination ophthalmic formulation consisting of **artificial tears**—a general term for lubricating eye drops used to relieve dryness and irritation of the ocular surface—and **benzalkonium chloride**, which is a quaternary ammonium compound used as a preservative. Artificial tears are typically composed of lubricating polymers (such as carboxymethylcellulose or polyethylene glycol), electrolytes, and other soothing agents that mimic or supplement natural tear film, providing relief for dryness and minor irritation. **Benzalkonium chloride** acts as a preservative by disrupting microbial cell membranes, thereby preventing contamination in multidose bottles. However, benzalkonium chloride is known to have cytotoxic effects: it disrupts the lipid layer of the tear film, damages epithelial cells, reduces goblet cell density, and can exacerbate or even induce dry eye syndrome and ocular surface inflammation with chronic use. The combination is used to manage symptoms of dry eye, ocular irritation, and related ocular surface disorders, but long-term use or frequent dosing—especially in sensitive individuals—may worsen symptoms due to benzalkonium chloride toxicity[1][2][4][5][6].

02

Targets

LPS (Lipopolysaccharide)ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on artificial tears + benzalkonium chloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on artificial tears + benzalkonium chloride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call